GSK chief calls on European governments to work with industry on defining value
This article was originally published in SRA
Andrew Witty, chief executive of GlaxoSmithKline and president of the European Federation of Pharmaceutical Industries and Associations, has called on European policy makers and pharmaceutical companies to work together to provide European citizens equal access to the right medicines and vaccines1. Speaking in Brussels at the "21st Century Healthcare for Europe" conference, Mr Witty acknowledged the need to restore the covenant between industry and governments.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.